Preliminary studies of EDDA-tricine-HYNIC-Tyr³-octreotide labelled with technetium-99m: radiopharmaceutical development for the diagnosis of neuroendocrine tumours
by Laura Terumi Ueda Hernandes Melero, Emiko Muramoto, Elaine Bortoleti De Araujo
Atoms for Peace: an International Journal (AFP), Vol. 3, No. 1, 2010

Abstract: The use of labelled molecules with high specificity for an organ or receptor in scintigraphy generates good local images and minimises the exposure of other organs. Octreotide was the first somatostatin synthetic analogue introduced in clinical use in the localisation of tumours with superexpression of somatostatin receptor (sstr). This work studied the labelling of HYNIC-Tyr3-octreotide with 99mTc and the biodistribution of labelled compounds in normal Swiss mice. A high radiochemical yield was obtained when using 20 μg of HYNIC-TOC, 10 mg of EDDA, 20 mg of tricine, 15 μg of SnCl2.2H2O, pH 7.5 and 10 min of boiling water bath. Biodistribution studies showed fast blood clearance of the labelled peptide with high kidney uptake and urinary excretion. The low background in the abdominal region is favourable for the diagnosis of neuroendocrine tumours.

Online publication date: Mon, 18-Jan-2010

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the Atoms for Peace: an International Journal (AFP):
Login with your Inderscience username and password:

    Username:        Password:         

Forgotten your password?


Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com